Find similar products:
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PL 25258/0159.
Olmesartan medoxomil 10 mg, 20 mg and 40 mg Film-coated Tablets
Olmesartan medoxomil 10 mg, 20 mg and 40 mg Film-coated Tablets
olmesartan medoxomil
1. What Olmesartan medoxomil is and what it is used for
2. What you need to know before you take Olmesartan medoxomil
3. How to take Olmesartan medoxomil
4. Possible side effects
5. How to store Olmesartan medoxomil
6. Contents of the pack and other information
Olmesartan medoxomil belongs to a group of medicines called angiotensin-II receptor antagonists. They lower blood pressure by relaxing the blood vessels.
The tablets are used for the treatment of high blood pressure (also known as “hypertension”) in adults and in children and adolescents aged 6 to less than 18 years. High blood pressure can damage blood vessels in organs such as the heart, kidneys, brain and eyes. In some cases this may lead to a heart attack, heart or kidney failure, stroke or blindness. Usually high blood pressure has no symptoms. It is important to have your blood pressure checked to prevent damage occurring.
High blood pressure can be controlled with medicines such as Olmesartan medoxomil . Your doctor has probably also recommended that you make some changes in your lifestyle to help lower your blood pressure (for example losing weight, giving up smoking, reducing the amount of alcohol you drink and reducing the amount of salt in your diet). Your doctor may also have urged you to take regular exercise, such as walking or swimming. It is important to follow this advice from your doctor.
Talk to your doctor or pharmacist before taking Olmesartan medoxomil:
Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals. See also information under the heading “Do not take Olmesartan medoxomil”.
Tell your doctor if you have any of the following health problems:
Contact your doctor if you experience diarrhoea that is severe, persistent and causes substantial weight loss. Your doctor may evaluate your symptoms and decide on how to continue your blood pressure medication.
As with any medicine which reduces blood pressure, an excessive drop in blood pressure in patients with blood flow disturbances of the heart or brain could lead to a heart attack or stroke. Your doctor will therefore check your blood pressure carefully.
You must tell your doctor if you think you are (or might become) pregnant. Olmesartan medoxomil is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).
Olmesartan medoxomil has been studied in children and adolescents. For more information, talk to your doctor. Olmesartan medoxomil is not recommended for children from 1 year to less than 6 years and should not be used in children under the age of 1 year as no experience is available.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any of the following medicines:
If you are over 65 years of age and your doctor decides to increase your dose of Olmesartan medoxomil to 40 mg daily, then you need to have your blood pressure regularly checked by your doctor to make sure that your blood pressure does not become too low.
As with other similar drugs the blood pressure lowering effect of Olmesartan medoxomil is somewhat less in black patients.
Olmesartan medoxomil can be taken with or without food.
Pregnancy
You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Olmesartan medoxomil before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Olmesartan medoxomil. Olmesartan medoxomil is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.
Breast-feeding
Tell your doctor if you are breast-feeding or about to start breast-feeding. Olmesartan medoxomil is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely. Ask your doctor or pharmacist for advice before taking any medicine.
You may feel sleepy or dizzy while being treated for your high blood pressure. If this happens, do not drive or use machines until the symptoms wear off. Ask your doctor for advice.
This medicine contains lactose (a type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
The recommended starting dose is one 10 mg tablet once a day. However, if your blood pressure is not controlled, your doctor may decide to change your dose up to 20 or 40 mg once a day, or prescribe additional medicines.
In patients with mild to moderate kidney disease, your dose will not be higher than 20 mg once a day.
The tablets can be taken with or without food. Swallow the tablets with a sufficient amount of water (e.g. one glass). If possible, take your daily dose at the same time each day, for example at breakfast time.
Children and adolescents from 6 to less than 18 years of age:
The recommended starting dose is 10 mg once daily. If the patient’s blood pressure is not adequately controlled, the doctor may decide to change the dose up to 20 or 40 mg once a day. In children who weigh less than 35 kg, the dose will not be higher than 20 mg once a day.
If you take more tablets than you should or if a child accidentally swallows some, go to your doctor or nearest emergency department immediately and take your medicine pack with you.
If you forget a dose, take your normal dose on the following day as usual. Do not take a double dose to make up for a forgotten tablet.
It is important to continue to take Olmesartan medoxomil unless your doctor tells you to stop.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. If they do occur, they are often mild and do not require treatment to be stopped.
Although not many people may get them, the following side effects can be serious: On rare occasions (may affect up to 1 in 1,000 people) the following allergic reactions, that may affect the whole body have been reported:
Swelling of the face, mouth and/or larynx (voice box) together with itching and rash may occur during treatment with Olmesartan medoxomil.
If this happens stop taking Olmesartan medoxomil and contact your doctor immediately.
Rarely (but slightly more often in older people) Olmesartan medoxomil can cause the blood pressure to fall too low in susceptible individuals or as the result of an allergic reaction. This could cause severe light-headedness or fainting.
If this occurs stop taking Olmesartan medoxomil, contact your doctor immediately and lie down flat.
These are the other side effects known about so far with Olmesartan medoxomil:
Common side effects (may affect up to 1 in 10 people):
Uncommon side effects (may affect up to 1 in 100 people):
Rare side effects (may affect up to 1 in 1,000 people):
Frequency not known: If you experience yellowing of the whites of the eyes, dark urine, itching of the skin, even if you started therapy with Olmesartan longer time ago, contact your doctor immediately who will evaluate your symptoms and decide on how to continue your blood pressure medication.
In children, side effects are similar to those reported in adults. However, dizziness and headache are seen more often in children, and nose bleeding is a common side effect seen in children only.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and the blister. The expiry date refers to the last day of that month.
This medicinal product does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Olmesartan medoxomil 10 mg tablets are white to off white, round film-coated tablets, debossed with 476 on one side and plain on the other side with a characteristic odour, approx. 6.3 mm in diameter.
Olmesartan medoxomil 20 mg tablets are white to off white, round film-coated tablets, debossed with 437 on one side and plain on the other side with a characteristic odour, approx. 8.6 mm in diameter.
Olmesartan medoxomil 40 mg tablets are white to off white, oval-shaped film-coated tablets debossed with 438 on one side and plain on the other side with a characteristic odour approx.15.3 mm in length and 7.2 mm in breadth.
Olmesartan medoxomil tablets are available in packs of 28, 30, 56, 90 and 98 film-coated tablets and packed in PVC/Alu/OPA – Alu blister packs.
Not all pack sizes may be marketed.
This medicinal product is authorised in the Member States of the EEA under the following names:
Netherlands Olmesartan medoxomil Glenmark 10 mg/20mg/40mg filmomhulde tabletten
Spain Olmesartan Viso Farmacéutica 10mg/20mg/40mg comprimidos recubiertos con película EFG
Germany Olmesartan Glenmark 10 mg/20mg/40mg Filmtablette
United Kingdom Olmesartan medoxomil 10 mg/20mg/40mg Film-coated Tablets
This leaflet was last revised in 03/2022.